{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:49:37Z","timestamp":1779310177199,"version":"3.51.4"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["CSC 202306170046"],"award-info":[{"award-number":["CSC 202306170046"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.smim.2025.101945","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T03:24:51Z","timestamp":1743218691000},"page":"101945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The immunological processes behind aquaporin 4-antibody seropositive neuromyelitis optica spectrum disorders"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2239-1586","authenticated-orcid":false,"given":"Monika","family":"Bradl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Takai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.smim.2025.101945_bib1","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.smim.2025.101945_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1209749","article-title":"Pathology of myelin oligodendrocyte glycoprotein antibody-associated disease: a comparison with multiple sclerosis and aquaporin 4 antibody-positive neuromyelitis optica spectrum disorders","volume":"14","author":"Takai","year":"2023","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.smim.2025.101945_bib4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00281-022-00941-9","article-title":"Immuno-pathogenesis of neuromyelitis optica and emerging therapies","volume":"44","author":"Chihara","year":"2022","journal-title":"Sem. Immunopathol."},{"key":"10.1016\/j.smim.2025.101945_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/2051-5960-1-85","article-title":"T cell-activation in neuromyelitis optica lesions plays a role in their formation","volume":"1","author":"Pohl","year":"2013","journal-title":"Acta Neuropathol. Commun."},{"issue":"6","key":"10.1016\/j.smim.2025.101945_bib7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00401-015-1501-5","article-title":"Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS","volume":"130","author":"Zeka","year":"2015","journal-title":"Acta Neuropathol."},{"issue":"5","key":"10.1016\/j.smim.2025.101945_bib8","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.smim.2025.101945_bib9","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. (USA)"},{"issue":"6","key":"10.1016\/j.smim.2025.101945_bib10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/acn3.418","article-title":"CNS Aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder","volume":"4","author":"Kowarik","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"3","key":"10.1016\/j.smim.2025.101945_bib11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00401-018-1950-8","article-title":"Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat","volume":"137","author":"Hillebrand","year":"2019","journal-title":"Acta Neuropathol."},{"issue":"Pt 5","key":"10.1016\/j.smim.2025.101945_bib12","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"issue":"14","key":"10.1016\/j.smim.2025.101945_bib13","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e318214332c","article-title":"Neruomyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications","volume":"76","author":"Popescu","year":"2011","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.smim.2025.101945_bib14","doi-asserted-by":"crossref","first-page":"e1642","DOI":"10.1212\/WNL.0000000000006392","article-title":"Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD","volume":"91","author":"Shosha","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib15","article-title":"Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro","volume":"4","author":"Takeshita","year":"2017","journal-title":"Neurol. (R. ) Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.smim.2025.101945_bib16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/glia.22635","article-title":"Neuromyelitis optica IgG stimulates an immunological response in rat astrocyte cultures","volume":"62","author":"Howe","year":"2014","journal-title":"Glia"},{"issue":"Pt 7","key":"10.1016\/j.smim.2025.101945_bib17","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"H. Lassmann, A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"issue":"17","key":"10.1016\/j.smim.2025.101945_bib18","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.1074\/jbc.M112.344325","article-title":"Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays","volume":"287","author":"Phuan","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"19","key":"10.1016\/j.smim.2025.101945_bib20","doi-asserted-by":"crossref","first-page":"12123","DOI":"10.1074\/jbc.M115.647149","article-title":"Mutagenesis of the aquaporin 4 extracellular domains defines restricted binding patterns of pathogenic neuromyelitis optica IgG","volume":"290","author":"Owens","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12974-016-0642-3","article-title":"Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders","volume":"13","author":"Tuller","year":"2016","journal-title":"J. Neuroinflamm."},{"issue":"1-2","key":"10.1016\/j.smim.2025.101945_bib22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jneuroim.2008.04.031","article-title":"CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome","volume":"199","author":"Bennett","year":"2008","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.smim.2025.101945_bib23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.autrev.2009.04.004","article-title":"Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica","volume":"9","author":"Saikali","year":"2009","journal-title":"Autoimm. Rev."},{"issue":"4","key":"10.1016\/j.smim.2025.101945_bib24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrd4226","article-title":"Aquaporins: important but elusive drug targets","volume":"13","author":"Verkman","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.smim.2025.101945_bib25","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamaneurol.2014.775","article-title":"Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum","volume":"71","author":"Guo","year":"2014","journal-title":"JAMA Neurol."},{"issue":"13","key":"10.1016\/j.smim.2025.101945_bib26","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/1352458515571446","article-title":"Role of membrane complement regulators in neuromyelitis optica","volume":"21","author":"Saadoun","year":"2015","journal-title":"Mult. Scler. J."},{"issue":"18","key":"10.1016\/j.smim.2025.101945_bib27","doi-asserted-by":"crossref","first-page":"16516","DOI":"10.1074\/jbc.M111.227298","article-title":"Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1\/M23 isoforms and orthogonal arrays","volume":"286","author":"Crane","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.smim.2025.101945_bib28","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000121","article-title":"Aquaporin-4 antibody isoform binding specificities do not explain clinical varations in NMO","volume":"2","author":"Kitley","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.smim.2025.101945_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010455","article-title":"Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica","volume":"5","author":"Mader","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.smim.2025.101945_bib30","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.smim.2025.101945_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/antib9040058","article-title":"The role of complement in the mechanism of action of therapeutic anti-cancer mAbs","volume":"9","author":"Golay","year":"2020","journal-title":"Antibodies"},{"issue":"4","key":"10.1016\/j.smim.2025.101945_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061835","article-title":"Characteristic cerebrospinal fluid cytokine\/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis","volume":"8","author":"Matsushita","year":"2013","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.smim.2025.101945_bib33","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.smim.2025.101945_bib34","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri1886","article-title":"Competence and competition: the challenge of becoming a long-lived plasma cell","volume":"6","author":"Radbruch","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.smim.2025.101945_bib35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12974-015-0240-9","article-title":"The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations","volume":"12","author":"Kowarik","year":"2015","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.smim.2025.101945_bib36","first-page":"77","article-title":"The binding property of a monoclonal antibody against the extracellular domains of aquaporin-4 directs aquaporin-4 toward endocytosis","volume":"7","author":"Huang","year":"2016","journal-title":"Biochem. Biophys. Rep."},{"issue":"8","key":"10.1016\/j.smim.2025.101945_bib37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1474-4422(11)70096-5","article-title":"Autoantibodies associated with diseases of the CNS: new developments and future challenges","volume":"10","author":"Vincent","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.smim.2025.101945_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.120825","article-title":"Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder in a paraneoplastic context","volume":"454","author":"Hyun","year":"2023","journal-title":"J. Neurol. Sci."},{"issue":"11","key":"10.1016\/j.smim.2025.101945_bib39","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2169\/internalmedicine.9783-22","article-title":"Paraneoplastic neuromyelitis optica spectrum disorder related to glucose-regulated protein 78 (GRP78) autoantibodies in a patient with lynch syndrome-associated colorectal cancer","volume":"62","author":"Minomo","year":"2023","journal-title":"Intern Med"},{"key":"10.1016\/j.smim.2025.101945_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.1071519","article-title":"Neuromyelitis optica spectrum disorders associated with AQP4-positive-cancer-A case series","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.smim.2025.101945_bib41","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurol"},{"issue":"4","key":"10.1016\/j.smim.2025.101945_bib42","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaut.2009.09.013","article-title":"The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes","volume":"34","author":"Sellner","year":"2010","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40478-020-00920-x","article-title":"Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes","volume":"8","author":"Tsymala","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"issue":"10","key":"10.1016\/j.smim.2025.101945_bib44","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1172\/JCI64413","article-title":"Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface","volume":"122","author":"Di Zenzo","year":"2012","journal-title":"J. Clin. Invest"},{"issue":"26","key":"10.1016\/j.smim.2025.101945_bib45","doi-asserted-by":"crossref","first-page":"9258","DOI":"10.1073\/pnas.0500132102","article-title":"The evolution of human anti-double-stranded DNA autoantibodies","volume":"102","author":"Wellmann","year":"2005","journal-title":"Proc. Natl. Acad. Sci. (USA)"},{"issue":"28","key":"10.1016\/j.smim.2025.101945_bib46","doi-asserted-by":"crossref","first-page":"9727","DOI":"10.1073\/pnas.0803644105","article-title":"Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors","volume":"105","author":"Mietzner","year":"2008","journal-title":"Proc. Natl. Acad. Sci. (USA)"},{"issue":"3","key":"10.1016\/j.smim.2025.101945_bib47","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.cell.2016.06.024","article-title":"AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies","volume":"166","author":"Meyer","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.smim.2025.101945_bib48","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1038\/ncomms8375","article-title":"Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis","volume":"6","author":"Piccoli","year":"2015","journal-title":"Nat. Comm."},{"key":"10.1016\/j.smim.2025.101945_bib49","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awz106","article-title":"Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production","author":"Cotzomi","year":"2019","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.smim.2025.101945_bib50","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/brain\/awy010","article-title":"Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica","volume":"141","author":"Wilson","year":"2018","journal-title":"Brain"},{"issue":"5638","key":"10.1016\/j.smim.2025.101945_bib51","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.1086907","article-title":"Predominant autoantibody production by early human B cell precursors","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.smim.2025.101945_bib52","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.coi.2008.09.001","article-title":"B-cell tolerance checkpoints in health and autoimmunity","volume":"20","author":"Meffre","year":"2008","journal-title":"Curr. Opin. Immunol."},{"issue":"397","key":"10.1016\/j.smim.2025.101945_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai9111","article-title":"Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica","volume":"9","author":"Shimizu","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.smim.2025.101945_bib54","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1172\/JCI78084","article-title":"Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity","volume":"125","author":"Suurmond","year":"2015","journal-title":"J. Clin. Invest"},{"issue":"12","key":"10.1016\/j.smim.2025.101945_bib55","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.4049\/jimmunol.1002722","article-title":"TLR ligation triggers somatic hypermutation in transitional B cells inducing the generation of IgM memory B cells","volume":"185","author":"Aranburu","year":"2010","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.smim.2025.101945_bib56","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1084\/jem.20122798","article-title":"Overexpression of TLR7 promotes cell-intrinsic expansion and autoantibody production by transitional T1 B cells","volume":"210","author":"Giltiay","year":"2013","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.smim.2025.101945_bib57","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/eji.200636878","article-title":"CpG DNA stimulates autoreactive immature B cells in the bone marrow","volume":"37","author":"Azulay-Debby","year":"2007","journal-title":"Eur. J. Immunol."},{"issue":"7909","key":"10.1016\/j.smim.2025.101945_bib58","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41586-022-04642-z","article-title":"TLR7 gain-of-function genetic variation causes human lupus","volume":"605","author":"Brown","year":"2022","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.smim.2025.101945_bib59","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","article-title":"Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus","volume":"49","author":"Jenks","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.smim.2025.101945_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.606338","article-title":"Specific induction of double negative b cells during protective and pathogenic immune responses","volume":"11","author":"Ruschil","year":"2020","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.smim.2025.101945_bib61","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archneur.65.7.913","article-title":"Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis","volume":"65","author":"Waters","year":"2008","journal-title":"Arch. Neurol."},{"issue":"397","key":"10.1016\/j.smim.2025.101945_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai9111","article-title":"Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica","volume":"9","author":"Shimizu","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.smim.2025.101945_bib63","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archneur.63.7.964","article-title":"Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib64","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00401-011-0824-0","article-title":"Pathogenic T cell responses against aquaporin 4","volume":"122","author":"Pohl","year":"2011","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.smim.2025.101945_bib65","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.immuni.2024.08.005","article-title":"Autontigen-specific CD4+\u2009T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases","volume":"57","author":"Saggau","year":"2024","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.smim.2025.101945_bib66","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/intimm\/dxr056","article-title":"Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica","volume":"23","author":"Matsuya","year":"2011","journal-title":"Int. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib67","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40478-016-0355-y","article-title":"Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMOSD","volume":"4","author":"Zeka","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"issue":"2","key":"10.1016\/j.smim.2025.101945_bib68","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/intimm\/9.2.281","article-title":"Definition of an extended MHC class II-peptide binding motif for the autoimmune disease-associated Lewis rat RT1.BL molecule","volume":"9","author":"Wauben","year":"1997","journal-title":"Int. Immunol."},{"issue":"11","key":"10.1016\/j.smim.2025.101945_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015050","article-title":"Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica","volume":"5","author":"Nelson","year":"2010","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016083","article-title":"Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica","volume":"6","author":"Kalluri","year":"2011","journal-title":"PloS One"},{"issue":"51","key":"10.1016\/j.smim.2025.101945_bib71","doi-asserted-by":"crossref","first-page":"14781","DOI":"10.1073\/pnas.1617859114","article-title":"Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4","volume":"113","author":"Sagan","year":"2016","journal-title":"Proc. Natl. Acad. Sci. (USA)"},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib72","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.23651","article-title":"Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter","volume":"72","author":"Varrin-Doyer","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.smim.2025.101945_bib73","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.msard.2015.12.004","article-title":"T-cell responses to distinct AQP4 peptides in patients with neuromyelitis optica (NMO)","volume":"6","author":"Vaknin-Dembinsky","year":"2016","journal-title":"Mult. Scler. Rel. Dis."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib74","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/s41467-018-04332-3","article-title":"A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica","volume":"9","author":"Estrada","year":"2018","journal-title":"Nat. Comm."},{"issue":"5","key":"10.1016\/j.smim.2025.101945_bib75","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/1352458508102085","article-title":"Is neuromyelitis optica associated with human leukocyte antigen?","volume":"15","author":"Zephir","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.smim.2025.101945_bib76","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3389\/fimmu.2020.01188","article-title":"Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases","volume":"11","author":"Hofer","year":"2020","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.smim.2025.101945_bib77","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/acn3.51147","article-title":"C. Japan Multiple Sclerosis Genetic, Genetic factors for susceptibility to and manifestations of neuromyelitis optica","volume":"7","author":"Matsushita","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib78","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/1352458510382810","article-title":"Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population","volume":"17","author":"Deschamps","year":"2011","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib79","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1352458509350741","article-title":"HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis","volume":"16","author":"Brum","year":"2010","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.smim.2025.101945_bib80","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.4103\/0028-3886.355130","article-title":"Association of HLA DRB1-DQB1 haplotypes with the risk for neuromyelitis optica among South Indians","volume":"70","author":"Kanikannan","year":"2022","journal-title":"Neurol. India"},{"issue":"3","key":"10.1016\/j.smim.2025.101945_bib81","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ana.24718","article-title":"Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens","volume":"80","author":"Cree","year":"2016","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib82","article-title":"Clostridium bolteae is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4","volume":"8","author":"Pandit","year":"2021","journal-title":"Neurol. (R. ) Neuroimm. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.smim.2025.101945_bib83","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0092-8674(95)90348-8","article-title":"Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein","volume":"80","author":"Wucherpfennig","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.smim.2025.101945_bib84","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40478-015-0207-1","article-title":"Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica","volume":"3","author":"Jones","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"issue":"8003","key":"10.1016\/j.smim.2025.101945_bib85","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41586-024-07079-8","article-title":"B cells orchestrate tolerance to the neuromyelitis optica autoantigen AQP4","volume":"627","author":"Afzali","year":"2024","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.smim.2025.101945_bib86","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.immuni.2015.05.013","article-title":"Thymic B cells are licensed to present self antigens for central T cell tolerance induction","volume":"42","author":"Yamano","year":"2015","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib87","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1046\/j.1365-2567.1998.00576.x","article-title":"NADPH diaphorase-positive dendritic profiles in rat thymus are discrete from autofluorescent cells, immunoreactive for inducible nitric oxide synthase, and show strain-specific abundance differences","volume":"95","author":"Downing","year":"1998","journal-title":"Immunol"},{"issue":"20","key":"10.1016\/j.smim.2025.101945_bib88","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients","volume":"78","author":"Leite","year":"2012","journal-title":"Neurol"},{"issue":"8","key":"10.1016\/j.smim.2025.101945_bib89","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/1352458511431728","article-title":"Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature","volume":"18","author":"Jarius","year":"2012","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.smim.2025.101945_bib90","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archneur.63.6.851","article-title":"Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy","volume":"63","author":"Kister","year":"2006","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib91","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.1038\/s41598-023-33827-3","article-title":"White blood cell count profiles in anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder and anti-myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"13","author":"Akaishi","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib92","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12974-017-0961-z","article-title":"Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder","volume":"14","author":"Kong","year":"2017","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.smim.2025.101945_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2016.09.011","article-title":"CD14(+)CD16(++) monocytes are increased in patients with NMO and are selectively suppressed by glucocorticoids therapy","volume":"300","author":"Zeng","year":"2016","journal-title":"J. Neuroimmun."},{"issue":"3","key":"10.1016\/j.smim.2025.101945_bib94","article-title":"Cell-free DNA derived from neutrophils triggers type 1 interferon signature in neuromyelitis optica spectrum disorder","volume":"9","author":"Murata","year":"2022","journal-title":"Neurol. (R. ) Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.smim.2025.101945_bib95","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/1352458515586084","article-title":"Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica","volume":"22","author":"Hertwig","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.smim.2025.101945_bib96","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2012.00368","article-title":"New insights for C5a and C5a receptors in sepsis","volume":"3","author":"Yan","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2025.101945_bib97","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3389\/fimmu.2018.01694","article-title":"C5a-Preactivated neutrophils are critical for autoimmune-induced astrocyte dysregulation in neuromyelitis optica spectrum disorder","volume":"9","author":"Piatek","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2025.101945_bib98","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1096\/fj.03-0708fje","article-title":"Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis","volume":"18","author":"Riedemann","year":"2004","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib99","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12974-022-02600-0","article-title":"Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD","volume":"19","author":"Schroeder-Castagno","year":"2022","journal-title":"J. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib100","article-title":"Long-term effects of IL-6 receptor blockade therapy on regulatory lymphocytes and neutrophils in neuromyelitis Optica Spectrum Disorder","volume":"11","author":"Matsuoka","year":"2024","journal-title":"Neurol. (R. ) Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.smim.2025.101945_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1415535","article-title":"Soluble biomarkers for Neuromyelitis Optica Spectrum Disorders: a mini review","volume":"15","author":"Rodin","year":"2024","journal-title":"Front. Neurol."},{"issue":"12","key":"10.1016\/j.smim.2025.101945_bib102","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.smim.2025.101945_bib103","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol. (R. ) Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.smim.2025.101945_bib104","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cca.2013.03.020","article-title":"Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks","volume":"421","author":"Uzawa","year":"2013","journal-title":"Clin. Chim. Acta"},{"issue":"4","key":"10.1016\/j.smim.2025.101945_bib105","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000494976","article-title":"Cytokines and tissue damage biomarkers in first-onset neuromyelitis optica spectrum disorders: significance of interleukin-6","volume":"25","author":"Wei","year":"2018","journal-title":"Neuroimmunomod"},{"issue":"3","key":"10.1016\/j.smim.2025.101945_bib106","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/jnnp.2011.241760","article-title":"CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse","volume":"83","author":"Uzawa","year":"2012","journal-title":"J. Neurol. Neurosurg. Psych."},{"issue":"3","key":"10.1016\/j.smim.2025.101945_bib107","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/cei.12733","article-title":"Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase","volume":"183","author":"Barros","year":"2016","journal-title":"Clin. Exp. Immunol."},{"issue":"13","key":"10.1016\/j.smim.2025.101945_bib108","first-page":"e1299","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurol"},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib109","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1084\/jem.169.1.333","article-title":"The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome","volume":"169","author":"Waage","year":"1989","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.smim.2025.101945_bib110","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib111","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ni.3632","article-title":"Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic T(H)17 cells","volume":"18","author":"Heink","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2025.101945_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155654","article-title":"Role of IL-6 in the commitment of T cell subsets","volume":"146","author":"Korn","year":"2021","journal-title":"Cytokine"},{"issue":"7","key":"10.1016\/j.smim.2025.101945_bib113","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nri2785","article-title":"FOXP3+\u2009regulatory T cells in the human immune system","volume":"10","author":"Sakaguchi","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"49","key":"10.1016\/j.smim.2025.101945_bib114","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw2262","article-title":"T(H)17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identity","volume":"5","author":"Harbour","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.smim.2025.101945_bib115","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.3389\/fimmu.2019.02686","article-title":"The balance in T follicular helper cell subsets is altered in neuromyelitis optica spectrum disorder patients and restored by rituximab","volume":"10","author":"Nicolas","year":"2019","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2025.101945_bib116","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41423-020-00608-1","article-title":"Interleukin-6 mediates neutrophil mobilization from bone marrow in pulmonary hypertension","volume":"18","author":"Florentin","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.smim.2025.101945_bib117","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1196\/annals.1321.009","article-title":"Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies","volume":"1024","author":"Franchimont","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.smim.2025.101945_bib118","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.smim.2025.101945_bib119","article-title":"Efficacy of plasma exchange in acute attacks of neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"350","author":"Yu","year":"2020","journal-title":"J. Neuroimmunol."},{"issue":"12","key":"10.1016\/j.smim.2025.101945_bib120","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1007\/s00415-020-10257-z","article-title":"Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis","volume":"268","author":"Siritho","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.smim.2025.101945_bib121","article-title":"Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy","volume":"49","author":"Takai","year":"2021","journal-title":"Mult. Scler. Rel. Dis."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib122","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1590\/S0004-282X2012000100012","article-title":"Treatment of neuromyelitis optica: an evidence based review","volume":"70","author":"Sato","year":"2012","journal-title":"Arq. Neuropsiquiatr."},{"issue":"3","key":"10.1016\/j.smim.2025.101945_bib123","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","article-title":"Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology","volume":"16","author":"Broen","year":"2020","journal-title":"Nat. Rev. Rheuma"},{"key":"10.1016\/j.smim.2025.101945_bib124","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.msard.2019.05.011","article-title":"Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis","volume":"33","author":"Espiritu","year":"2019","journal-title":"Mult. Scler. Rel. Dis."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12883-018-1056-x","article-title":"Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study","volume":"18","author":"Jiao","year":"2018","journal-title":"BMC Neurol."},{"issue":"8","key":"10.1016\/j.smim.2025.101945_bib126","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1093\/brain\/awab102","article-title":"Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders","volume":"144","author":"Takai","year":"2021","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.smim.2025.101945_bib127","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2025.101945_bib128","article-title":"Immunological basis of the endometriosis: the complement system as a potential therapeutic target","volume":"11","author":"Agostinis","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e05899","article-title":"CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder","volume":"7","author":"Namatame","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.smim.2025.101945_bib130","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.696387","article-title":"Eculizumab pharmacokinetics and pharmacodynamics in patients with neuromyelitis optica spectrum disorder","volume":"12","author":"Singh","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.smim.2025.101945_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110081","article-title":"The anaphylatoxin C5a: Structure, function, signaling, physiology, disease, and therapeutics","volume":"118","author":"Ghosh","year":"2023","journal-title":"Int. Immunopharm."},{"issue":"4","key":"10.1016\/j.smim.2025.101945_bib132","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s13760-023-02261-7","article-title":"C5a complement levels in clinical remission AQP4-IgG-positive NMO patients","volume":"123","author":"Manin","year":"2023","journal-title":"Acta Neurol. Belg."},{"issue":"1-2","key":"10.1016\/j.smim.2025.101945_bib133","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jneuroim.2012.09.002","article-title":"Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica","volume":"254","author":"Kuroda","year":"2013","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.smim.2025.101945_bib134","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12974-022-02661-1","article-title":"Upregulated complement receptors correlate with Fc gamma receptor 3A-positive natural killer and natural killer-T cells in neuromyelitis optica spectrum disorder","volume":"19","author":"Nishiyama","year":"2022","journal-title":"J. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.smim.2025.101945_bib135","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.smim.2025.101945_bib136","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.smim.2025.101945_bib137","article-title":"Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: an update systematic review and meta -analysis","volume":"50","author":"Wang","year":"2021","journal-title":"Mult. Scler. Rel. Dis."},{"issue":"15","key":"10.1016\/j.smim.2025.101945_bib138","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurol"},{"issue":"2","key":"10.1016\/j.smim.2025.101945_bib139","article-title":"Aquaporin-4 antibody titration in NMO patients treated with rituximab: a retrospective study","volume":"4","author":"Valentino","year":"2017","journal-title":"Neurol. (R. ) Neuroimmunol. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.smim.2025.101945_bib140","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jocn.2010.12.011","article-title":"Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels","volume":"18","author":"Nakashima","year":"2011","journal-title":"J. Clin. Neurosci."},{"issue":"9","key":"10.1016\/j.smim.2025.101945_bib141","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.smim.2025.101945_bib142","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418761697","article-title":"B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets","volume":"11","author":"Forsthuber","year":"2018","journal-title":"Ther. Adv. Neurol. Dis."},{"key":"10.1016\/j.smim.2025.101945_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.smim.2025.101945_bib144","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.smim.2025.101945_bib145","article-title":"Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study","volume":"57","author":"Flanagan","year":"2022","journal-title":"Mult. Scler. Rel. Dis."},{"issue":"3","key":"10.1016\/j.smim.2025.101945_bib146","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2013.668","article-title":"Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses","volume":"70","author":"Kieseier","year":"2013","journal-title":"JAMA Neurol."},{"issue":"15","key":"10.1016\/j.smim.2025.101945_bib147","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurol"},{"issue":"5","key":"10.1016\/j.smim.2025.101945_bib148","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"T.S. Investigators, Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."},{"issue":"22","key":"10.1016\/j.smim.2025.101945_bib149","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.smim.2025.101945_bib150","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.smim.2025.101945_bib151","article-title":"New BBB model reveals that IL-6 blockade suppressed the BBB disorder, preventing onset of NMOSD","volume":"8","author":"Takeshita","year":"2021","journal-title":"Neurol. (R. ) Neuroimmunol. Neuroinflamm."},{"issue":"10","key":"10.1016\/j.smim.2025.101945_bib152","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s40263-022-00949-7","article-title":"Inebilizumab: a review in neuromyelitis Optica Spectrum Disorder","volume":"36","author":"Nie","year":"2022","journal-title":"CNS Drugs"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104453232500017X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104453232500017X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:46:03Z","timestamp":1778795163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104453232500017X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":152,"alternative-id":["S104453232500017X"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2025.101945","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immunological processes behind aquaporin 4-antibody seropositive neuromyelitis optica spectrum disorders","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2025.101945","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101945"}}